NEW YORK, April 17, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Clovis Oncology (NASDAQ: CLVS), DBV Technologies (NASDAQ: DBVT), Cleveland BioLabs (NASDAQ: CBLI), Arrowhead Research (NASDAQ: ARWR), and Athenahealth (NASDAQ: ATHN). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
CLVS Research Report: ( http://get.analystsreview.com/pdf/?c=Clovis%20Oncology&d=17-Apr-2015&s=CLVS ),
DBVT Research Report: ( http://get.analystsreview.com/pdf/?c=DBV%20Tech&d=17-Apr-2015&s=DBVT ),
CBLI Research Report: ( http://get.analystsreview.com/pdf/?c=Cleveland%20BioLabs&d=17-Apr-2015&s=CBLI ),
ARWR Research Report: ( http://get.analystsreview.com/pdf/?c=Arrowhead%20Research&d=17-Apr-2015&s=ARWR ),
ATHN Research Report: ( http://get.analystsreview.com/pdf/?c=athenahealth&d=17-Apr-2014&s=ATHN ).
Analyst Update: Rating Upgrades, Partnerships, FDA Designations and Approvals
Reviewed by: Rohit Tuli, CFA®
US stocks ended marginally lower on Thursday, as worries about upcoming corporate earnings reports offset enthusiasm about a trio of soaring Wall Street debuts. The Dow Jones industrial average fell 6.84 points, or 0.04%, to end at 18,105.77; the S&P 500 lost 1.64 points, or 0.08%, to 2,104.99; and the Nasdaq Composite dropped 3.23 points, or 0.06%, to 5,007.79. European markets finished broadly lower on Thursday with growing concerns about Greece's debt situation prompting investors to take some profits after the previous session's 14-year highs. The DAX closed 1.94% lower, France's CAC 40 declined by 0.57% and London's FTSE 100 declined by 0.51%. The pan-European FTSEurofirst 300 index closed 0.9% lower at 1,635.76 points. Chinese shares rebounded on stimulus hopes a day after gloomy first-quarter economic numbers with the Shanghai composite index rising 2.1% to 4,168.85, while other Asian benchmarks were mixed.
Clovis Oncology Inc. (Clovis) was upgraded by Goldman Sachs analysts from Neutral to Buy, according to an article released on Yahoo finance on April 13, 2015. Goldman Sachs also raised its price target on the stock from $68 to $117. The news drove up the Company's share prices, which opened 9.2% higher on Monday Morning at $84.50 and rallied further over the day, closing at $87.49.
DBV Technologies SA (DBV) announced on April 09, 2015 that it has received FDA Breakthrough Therapy Designation for Viaskin Peanut for the Treatment of peanut allergy in children. The share prices closed up 5.5% on the same day.
Cleveland BioLabs Inc (Cleveland) stock opened up 7.6% higher on April 14, 2014. The Company announced on the same day that it has received a notice that a second proposal application to support further development of entolimod as a medical radiation countermeasure has been recommended for funding, subject to negotiations, by the Department of Defense (DoD) office of Congressionally Directed Medical Research Programs (CDMRP).
Shares of Arrowhead Research Corp. (Arrowhead) showed unusual volumes on the back of getting FDA approval to conduct a multiple dose Phase 2b Study of ARC-520, its lead hepatitis B drug, on April 13, 2015. The stock closed at $8.0 registering a gain of 1%.
On April 13, 2015, Trinity Health, one of the nation's leading and largest health systems, and athenahealth, Inc. (Athena), a leading provider of cloud-based services and mobile applications for medical groups and health systems, announced that they will work together to advance clinical integration and people-centered care in the health system's multi-state ambulatory network.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review